Research graph
References from From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1002/ajh.27422
10.1002/ajh.27422 · External reference
10.3390/jcm14051655
10.3390/jcm14051655 · External reference
10.1002/hon.70067
10.1002/hon.70067 · External reference
10.1016/j.clml.2024.11.012
10.1016/j.clml.2024.11.012 · External reference
10.1200/edbk_200869
10.1200/edbk_200869 · External reference
10.3390/cancers13040625
10.3390/cancers13040625 · External reference
10.1038/s41419-022-04651-w
10.1038/s41419-022-04651-w · External reference
10.1097/01.hs9.0000970380.84060.bf
10.1097/01.hs9.0000970380.84060.bf · External reference
10.1038/s41408-024-01191-8
10.1038/s41408-024-01191-8 · External reference
10.1038/s41434-021-00254-w
10.1038/s41434-021-00254-w · External reference
10.1016/j.biopha.2023.115888
10.1016/j.biopha.2023.115888 · External reference
10.1038/s41408-025-01330-9
10.1038/s41408-025-01330-9 · External reference
10.1056/nejmoa2303379
10.1056/nejmoa2303379 · External reference
10.2217/fon-2023-0954
10.2217/fon-2023-0954 · External reference
10.1182/blood-2007-10-078022
10.1182/blood-2007-10-078022 · External reference
10.3389/fonc.2022.974038
10.3389/fonc.2022.974038 · External reference
10.1016/j.bbmt.2016.11.011
10.1016/j.bbmt.2016.11.011 · External reference
10.1016/s1470-2045(25)00018-x
10.1016/s1470-2045(25)00018-x · External reference
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
External reference
10.1016/s2352-3026(23)00217-x
10.1016/s2352-3026(23)00217-x · External reference
10.1200/jco.2025.43.16_suppl.7503
10.1200/jco.2025.43.16_suppl.7503 · External reference
10.1182/blood-2020-143459
10.1182/blood-2020-143459 · External reference
10.1016/j.clml.2023.02.009
10.1016/j.clml.2023.02.009 · External reference
10.1038/s41375-024-02505-2
10.1038/s41375-024-02505-2 · External reference
10.1016/s2152-2650(20)30470-5
10.1016/s2152-2650(20)30470-5 · External reference
10.3389/fonc.2024.1282300
10.3389/fonc.2024.1282300 · External reference
10.1177/15330338251321349
10.1177/15330338251321349 · External reference
10.1056/nejmoa2204925
10.1056/nejmoa2204925 · External reference
10.1038/s41408-024-01198-1
10.1038/s41408-024-01198-1 · External reference
10.1038/s41598-017-16561-5
10.1038/s41598-017-16561-5 · External reference
10.3390/medsci11010014
10.3390/medsci11010014 · External reference
10.1002/jca.21361
10.1002/jca.21361 · External reference
10.1016/j.stem.2024.10.013
10.1016/j.stem.2024.10.013 · External reference
10.1016/j.blre.2023.101162
10.1016/j.blre.2023.101162 · External reference
10.1111/ejh.13650
10.1111/ejh.13650 · External reference
10.18632/oncotarget.19152
10.18632/oncotarget.19152 · External reference
10.1016/j.bbmt.2012.11.466
10.1016/j.bbmt.2012.11.466 · External reference
10.1038/s41408-024-01120-9
10.1038/s41408-024-01120-9 · External reference
10.1038/s41408-023-00864-0
10.1038/s41408-023-00864-0 · External reference
10.1182/blood.2023021781
10.1182/blood.2023021781 · External reference
10.1038/ncomms3997
10.1038/ncomms3997 · External reference
10.1200/jco.21.02815
10.1200/jco.21.02815 · External reference
Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond
External reference
10.18632/oncotarget.5800
10.18632/oncotarget.5800 · External reference
10.1007/s12288-025-02008-9
10.1007/s12288-025-02008-9 · External reference
10.3390/cancers15143687
10.3390/cancers15143687 · External reference
10.1016/j.clml.2024.02.013
10.1016/j.clml.2024.02.013 · External reference
10.1159/000539127
10.1159/000539127 · External reference
10.1111/bjh.13532
10.1111/bjh.13532 · External reference
10.1182/blood-2024-193205
10.1182/blood-2024-193205 · External reference
10.1038/nrrheum.2015.160
10.1038/nrrheum.2015.160 · External reference
10.1177/0897190020977763
10.1177/0897190020977763 · External reference
Bortezomib-induced hepatotoxicity in a patient with multiple myeloma: a case report
2024 · External reference
10.4081/hr.2015.5704
10.4081/hr.2015.5704 · External reference
10.1038/s41408-023-00849-z
10.1038/s41408-023-00849-z · External reference
10.1056/nejmoa2312054
10.1056/nejmoa2312054 · External reference
10.1200/jco.2025.43.16_suppl.7535
10.1200/jco.2025.43.16_suppl.7535 · External reference
10.1111/ejh.14365
10.1111/ejh.14365 · External reference
10.1182/bloodadvances.2023010026
10.1182/bloodadvances.2023010026 · External reference
10.1080/13696998.2023.2207742
10.1080/13696998.2023.2207742 · External reference
10.1097/01.hs9.0000829588.31575.a9
10.1097/01.hs9.0000829588.31575.a9 · External reference
10.1007/s10198-021-01335-8
10.1007/s10198-021-01335-8 · External reference
10.1016/j.clml.2025.08.017
10.1016/j.clml.2025.08.017 · External reference
10.1038/s41408-020-00357-4
10.1038/s41408-020-00357-4 · External reference
10.1182/bloodadvances.2024014717
10.1182/bloodadvances.2024014717 · External reference
10.1038/s41408-023-00797-8
10.1038/s41408-023-00797-8 · External reference
10.1016/s0140-6736(19)32556-5
10.1016/s0140-6736(19)32556-5 · External reference
Unresolved reference
External reference
10.1186/s13045-024-01530-z
10.1186/s13045-024-01530-z · External reference
10.1200/jco-25-00760
10.1200/jco-25-00760 · External reference
10.1002/ajh.26261
10.1002/ajh.26261 · External reference
10.1038/s41417-024-00750-2
10.1038/s41417-024-00750-2 · External reference
10.3389/fimmu.2022.991092
10.3389/fimmu.2022.991092 · External reference
10.1084/jem.20230903
10.1084/jem.20230903 · External reference
10.1159/000539134
10.1159/000539134 · External reference
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
2023 · External reference
10.1111/jcmm.17930
10.1111/jcmm.17930 · External reference
10.3324/haematol.2024.286027
10.3324/haematol.2024.286027 · External reference
10.1016/j.beha.2024.101566
10.1016/j.beha.2024.101566 · External reference
10.2217/fon-2021-1090
10.2217/fon-2021-1090 · External reference
10.1056/nejmoa2024850
10.1056/nejmoa2024850 · External reference
10.1182/blood-2023-178882
10.1182/blood-2023-178882 · External reference
10.1182/blood.2022015526
10.1182/blood.2022015526 · External reference
10.1016/s2152-2650(24)01694-x
10.1016/s2152-2650(24)01694-x · External reference
10.1182/blood-2021-146210
10.1182/blood-2021-146210 · External reference
10.1097/01.hs9.0000936220.68605.8b
10.1097/01.hs9.0000936220.68605.8b · External reference
10.1016/s2352-3026(24)00320-x
10.1016/s2352-3026(24)00320-x · External reference
10.1056/nejmoa2213614
10.1056/nejmoa2213614 · External reference
10.1056/nejmoa2203478
10.1056/nejmoa2203478 · External reference
10.1056/nejmoa2204591
10.1056/nejmoa2204591 · External reference
10.1038/s41591-023-02528-9
10.1038/s41591-023-02528-9 · External reference
10.1200/jco.24.01008
10.1200/jco.24.01008 · External reference
Access to Bispecific Therapies for Multiple Myeloma: An Overview of Barriers and Emerging Solutions
2026 · External reference
10.1038/s41598-024-83861-y
10.1038/s41598-024-83861-y · External reference
10.1007/bf00451727
10.1007/bf00451727 · External reference
10.1016/j.jval.2011.11.029
10.1016/j.jval.2011.11.029 · External reference
10.1016/j.jtho.2019.07.007
10.1016/j.jtho.2019.07.007 · External reference
10.1016/j.jval.2015.09.1267
10.1016/j.jval.2015.09.1267 · External reference
10.1186/1477-7525-5-70
10.1186/1477-7525-5-70 · External reference
The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER’s reports
2021 · External reference
10.1016/j.bbmt.2012.08.011
10.1016/j.bbmt.2012.08.011 · External reference
10.3322/caac.21706
10.3322/caac.21706 · External reference
10.1182/blood-2018-09-825331
10.1182/blood-2018-09-825331 · External reference
10.1038/s41408-025-01253-5
10.1038/s41408-025-01253-5 · External reference
10.1200/jco.23.02771
10.1200/jco.23.02771 · External reference
10.1177/2040620716652862
10.1177/2040620716652862 · External reference
10.3892/mco.2023.2705
10.3892/mco.2023.2705 · External reference
10.1016/j.lfs.2024.123125
10.1016/j.lfs.2024.123125 · External reference
10.1146/annurev-pharmtox-010919-023603
10.1146/annurev-pharmtox-010919-023603 · External reference
10.1007/s40265-017-0833-y
10.1007/s40265-017-0833-y · External reference
10.3390/lymphatics3010002
10.3390/lymphatics3010002 · External reference
